Do Increased Doses to Stem-Cell Niches during Radiation Therapy Improve Glioblastoma Survival?

Table 3

Univariate proportional-hazards regression analysis of cofactors on progression-free survival in glioblastoma patients with conventionally fractionated radiotherapy.

Cofactors	HR	95% CI	value
Karnofsky performance status > 80	1.16	0.68–1.96	0.59
Peripheral versus central	0.85	0.51–1.39	0.51
MGMT promoter methylation	0.93	0.68–1.34	0.60
Biopsy versus surgical resection	0.48	0.22–1.03	0.06
Gross total resection versus subtotal resection	0.70	0.41–1.40	0.38
Temozolomide therapy	0.60	0.32–1.09	0.09
Mean IL ventricle dose ≥ 40 Gy	0.56	0.32–0.98	0.043
Mean CL ventricle dose ≥ 40 Gy	0.61	0.26–1.44	0.26
Mean IL SVZ dose ≥ 40 Gy	0.40	0.24–0.78	0.002
Mean CL SVZ dose ≥ 30 Gy	0.44	0.21–0.92	0.030
Mean IL DG dose ≥ 40 Gy	1.42	0.81–2.51	0.22
Mean CL DG dose ≥ 30 Gy	0.86	0.31–2.40	0.77

CI: confidence interval; HR: hazard ratio; IL: ipsilateral; CL: contralateral; SVZ: subventricular zone; DG: dentate gyrus; Gy: gray; MGMT: O-6-methylguanine methyltransferase; RT: radiation therapy.